Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness.

Bourdette D, Whitham R.

Neurology. 2016 Oct 11;87(15):1532-1533. Epub 2016 Sep 2. No abstract available.

PMID:
27590289
2.

Author response: Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness.

Bourdette DN.

Neurology. 2017 Aug 1;89(5):520-521. doi: 10.1212/WNL.0000000000004194. No abstract available.

PMID:
28760917
3.

Letter re: Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness.

Otulana T.

Neurology. 2017 Aug 1;89(5):520. doi: 10.1212/WNL.0000000000004193. No abstract available.

PMID:
28760916
4.

Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study.

Lin PJ, Saret CJ, Neumann PJ, Sandberg EA, Cohen JT.

Pharmacoeconomics. 2016 Dec;34(12):1255-1265.

PMID:
27461538
5.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.

PMID:
28139062
6.

Access to and utilization of neurologists by people with multiple sclerosis.

Minden SL, Hoaglin DC, Hadden L, Frankel D, Robbins T, Perloff J.

Neurology. 2008 Mar 25;70(13 Pt 2):1141-9. doi: 10.1212/01.wnl.0000306411.46934.ef.

PMID:
18362274
7.

[Quality of life and economic cost of multiple sclerosis].

Grimaud J, Auray JP; Collectif SEP des villes et SEP des champs.

Rev Neurol (Paris). 2004 Jan;160(1):23-34. Review. French.

PMID:
14978391
8.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain.

Karampampa K, Gustavsson A, Miltenburger C, Mora S, Arbizu T.

Mult Scler. 2012 Jun;18(2 Suppl):35-9. doi: 10.1177/1352458512441566d. No abstract available.

PMID:
22623126
9.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy.

Karampampa K, Gustavsson A, Miltenburger C, Teruzzi C, Fattore G.

Mult Scler. 2012 Jun;18(2 Suppl):29-34. doi: 10.1177/1352458512441566c. No abstract available.

PMID:
22623125
10.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany.

Karampampa K, Gustavsson A, Miltenburger C, Neidhardt K, Lang M.

Mult Scler. 2012 Jun;18(2 Suppl):23-7. doi: 10.1177/1352458512441566b. No abstract available.

PMID:
22623124
11.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France.

Johansson E, Gustavsson A, Miltenburger C, Karampampa K, Rumbach L, Rérat K, Thonnelier C.

Mult Scler. 2012 Jun;18(2 Suppl):17-22. doi: 10.1177/1352458512441566a. No abstract available.

PMID:
22623123
12.

Reducing costs while enhancing quality of care in MS.

Kister I, Corboy JR.

Neurology. 2016 Oct 11;87(15):1617-1622. Epub 2016 Sep 2.

13.

Caught in a no-win situation: discussions about CCSVI between persons with multiple sclerosis and their neurologists - a qualitative study.

Driedger SM, Maier R, Marrie RA, Brouwers M.

BMC Neurol. 2017 Sep 7;17(1):176. doi: 10.1186/s12883-017-0954-7.

14.

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.

Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, Duddy M, Dobson C.

BMJ Open. 2014 Jan 17;4(1):e004073. doi: 10.1136/bmjopen-2013-004073. Erratum in: BMJ Open. 2014;4(1):e004073corr1. Zhu, Fheng [corrected to Zhu, Feng].

15.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom.

Karampampa K, Gustavsson A, Miltenburger C, Tyas D.

Mult Scler. 2012 Jun;18(2 Suppl):41-5. doi: 10.1177/1352458512441566e. No abstract available.

PMID:
22623127
16.

Having the conversation about work with people with multiple sclerosis: a guide for healthcare professionals.

Cardone A.

Neurodegener Dis Manag. 2017 Nov;7(6s):41-44. doi: 10.2217/nmt-2017-0041.

PMID:
29143585
17.

Interferons should be used to treat most patients with MS.

Herndon RM, Jacobs L.

Arch Neurol. 1998 Dec;55(12):1581-3. No abstract available.

PMID:
9865806
18.

Cost-effectiveness of disease-modifying therapies in multiple sclerosis.

Manouchehrinia A, Constantinescu CS.

Curr Neurol Neurosci Rep. 2012 Oct;12(5):592-600. doi: 10.1007/s11910-012-0291-6. Review.

PMID:
22782520
19.

[Economic repercussions of multiple sclerosis].

Marissal JP, Hautecoeur P.

Pathol Biol (Paris). 2000 Mar;48(2):139-50. Review. French.

PMID:
10815290
20.

[Editorial: multiple sclerosis].

Vermersch P.

Rev Neurol (Paris). 2009 Mar;165 Suppl 4:S111. doi: 10.1016/S0035-3787(09)72121-6. French. No abstract available.

PMID:
19361674

Supplemental Content

Support Center